IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...

Trinasolar, a global leader in smart PV and energy storage, has partnered with Smart Commercial Solar to deliver an advanced ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Pharmaceutical giant AstraZeneca has transformed an underused space at its Sydney headquarters into a renewable energy asset ...

Daily pill on NHS offers new hope for hundreds with lung cancer - Osimertinib, also known as Tagrisso and made by AstraZeneca ...

DelveInsight's“Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bullous Pemphigoid, historical and forecasted epidemiology as ...

According to Nice, osimertinib can help stop cancer from returning after surgery by targeting cells that have specific mutations.

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

IonQ's strong revenue growth and partnerships with industry leaders are promising, but high operating expenses and reliance ...